{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marstrand P"],"funding":["the FUKAP foundation","fondsbørsvekselerer Henry Hansen og hustrus legat","Hjerteforeningen","Købmand Sven Hansen og Hustru Ina Hansens Fond","Fonden til Lægevidenskabens Fremme","Lundbeckfonden","Novo Nordisk Fonden","Lundbeck Foundation"],"pagination":["e001670"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8449979"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(2)"],"pubmed_abstract":["<h4>Background</h4>In long QT syndrome (LQTS), beta blockers prevent arrhythmias. As a supplement, means to increase potassium has been suggested. We set to investigate the effect of moderate potassium elevation on cardiac repolarisation.<h4>Methods</h4>Patients with LQTS with a disease-causing <i>KCNQ1</i> or <i>KCNH2</i> variant were included. In addition to usual beta-blocker treatment, patients were prescribed (1) 50 mg spironolactone (<i>low dose</i>) or (2) 100 mg spironolactone and 3 g potassium chloride per day (<i>high dose+</i>). Electrocardiographic measures were obtained at baseline and after 7 days of treatment.<h4>Results</h4>Twenty patients were enrolled (10 low dose and 10 high dose+). One patient was excluded due to severe influenza-like symptoms, and 5 of 19 patients comp"],"journal":["Open heart"],"pubmed_title":["Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study."],"pmcid":["PMC8449979"],"funding_grant_id":["NNF20OC0065799","Grant 17-R115-A7532-22065","R358-2020-2343"],"pubmed_authors":["Graff C","Bundgaard H","Christensen AH","Theilade J","Almatlouh K","Marstrand P","Kanters JK"],"additional_accession":[]},"is_claimable":false,"name":"Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.","description":"<h4>Background</h4>In long QT syndrome (LQTS), beta blockers prevent arrhythmias. As a supplement, means to increase potassium has been suggested. We set to investigate the effect of moderate potassium elevation on cardiac repolarisation.<h4>Methods</h4>Patients with LQTS with a disease-causing <i>KCNQ1</i> or <i>KCNH2</i> variant were included. In addition to usual beta-blocker treatment, patients were prescribed (1) 50 mg spironolactone (<i>low dose</i>) or (2) 100 mg spironolactone and 3 g potassium chloride per day (<i>high dose+</i>). Electrocardiographic measures were obtained at baseline and after 7 days of treatment.<h4>Results</h4>Twenty patients were enrolled (10 low dose and 10 high dose+). One patient was excluded due to severe influenza-like symptoms, and 5 of 19 patients comp","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-06-15T06:09:03.088Z","creation":"2026-06-15T03:08:29.979Z"},"accession":"S-EPMC8449979","cross_references":{"pubmed":["34531279"],"doi":["10.1136/openhrt-2021-001670"]}}